ResultsIQ

ResultsIQ › Latest results › Krishna Institute of Medical Sciences Limited

Krishna Institute of Medical Sciences Limited Q2 FY26 results deck summary

NSE: KIMS · BSE: 543308

Results deck of 7 Nov 2025, summarised by AI from the filing.

Q2 FY26 total revenue ₹9,649 mn, up 23.3% YoY, but EBITDA margin fell to 21.6% from 28.5% in Q2 FY25.

Key takeaways

  1. Revenue Q2 FY26 total revenue ₹9,649 mn, up 23.3% YoY and 9.8% QoQ.
  2. EBITDA Q2 FY26 EBITDA ₹2,082 mn, down 6.7% YoY; margin 21.6% vs 28.5% in Q2 FY25.
  3. PAT Q2 FY26 PAT ₹720 mn against ₹1,207 mn in Q2 FY25 and ₹850 mn in Q1 FY26.
  4. Margin pressure EBITDA margin declined to 21.6% in Q2 FY26 from 28.5% in Q2 FY25.

Original filing on BSE

Krishna Institute of Medical Sciences Limited Q1 FY27 results

As filed: Revenue ₹1,180 cr (+35% year on year), EBITDA ₹223 cr (+16% year on year), PAT ₹37.4 cr (−56% year on year), EBITDA margin 18.9% (−319 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,075 cr (+35% year on year), EBITDA ₹207 cr (+4% year on year), PAT ₹33.1 cr (−49% year on year), EBITDA margin 19.2% (−563 bps). Score 43 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin fell 563 bps year on year. Tax rate 42%. Profit fell 8% from last quarter. Share price after the results: +3.1% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹998 cr (+29% year on year), EBITDA ₹199 cr (+6% year on year), PAT ₹51.9 cr (−44% year on year), EBITDA margin 19.9% (−442 bps). Score 46 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 442 bps year on year. Profit fell 28% from last quarter. Share price after the results: +21.1% in 28 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹961 cr (+24% year on year), EBITDA ₹204 cr (−6% year on year), PAT ₹72.0 cr (−41% year on year), EBITDA margin 21.2% (−683 bps). Score 34 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 683 bps year on year. Profit fell 15% from last quarter. Revenue rose ₹184 cr on a year ago, more than the ₹125 cr it added the year before. Share price after the results: −2.3% in 28 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹872 cr (+27% year on year), EBITDA ₹193 cr (+8% year on year), PAT ₹85.0 cr (−11% year on year), EBITDA margin 22.1% (−388 bps). Score 50 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 388 bps year on year. Profit fell 20% from last quarter. Revenue rose ₹184 cr on a year ago, more than the ₹82.0 cr it added the year before. Share price after the results: +0.3% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹797 cr (+26% year on year), EBITDA ₹198 cr (+25% year on year), PAT ₹106 cr (+49% year on year), EBITDA margin 24.8% (−8 bps). Score 81 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin was flat year on year. Revenue rose ₹163 cr on a year ago, more than the ₹58.0 cr it added the year before. Share price after the results: +3.0% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹772 cr (+27% year on year), EBITDA ₹188 cr (+28% year on year), PAT ₹93.0 cr (+21% year on year), EBITDA margin 24.4% (+9 bps). Score 82 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin was flat year on year. Profit fell 23% from last quarter.
  • Q2 FY25: Revenue ₹777 cr (+19% year on year), EBITDA ₹218 cr (+22% year on year), PAT ₹121 cr (+20% year on year), EBITDA margin 28.1% (+76 bps). Score 65 of 100, Above trend. EBITDA margin rose 76 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Krishna Institute of Medical Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.